30233C0
Transfusion Peripheral Vein to Autologous with Hematopoietic Stem/Progenitor Cells, Genetically Modified, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | 3 Administration |
| Body System | 0 Circulatory |
| Operation | 2 Transfusion |
| Body Part | 3 Peripheral Vein |
| Approach | 3 Percutaneous |
| Device | C Hematopoietic Stem/Progenitor Cells, Genetically Modified |
| Qualifier | 0 Autologous |
Operation Definition
Putting in blood or blood products
Procedure Overview
Transfusion is the administration of blood or a blood-derived product directly into a patient's circulation, most commonly packed red blood cells, platelets, fresh frozen plasma, or cryoprecipitate. It is used to treat significant blood loss, severe anemia, clotting disorders, or shortages of specific blood components caused by disease or treatment such as chemotherapy.
For a patient, a transfusion means receiving donated or, less commonly, their own previously collected blood through an intravenous line. The goal is to quickly restore oxygen-carrying capacity, clotting ability, or blood volume when the body cannot do so on its own. Transfusions are generally short procedures performed at the bedside, though the underlying condition prompting them can range from routine surgical blood loss to a life-threatening hemorrhage.
Anatomy & Axis Detail
Peripheral Vein
A peripheral vein, such as one in the forearm or hand, is the most common access point for transfusing whole blood or blood products in routine clinical care. Its superficial location allows straightforward cannulation with a standard intravenous catheter, making it the default route unless rapid large-volume administration or vascular fragility necessitates central access. Transfusion via peripheral vein is used for red cells, platelets, plasma, or cryoprecipitate in settings ranging from anemia correction to trauma resuscitation, and the vessel's smaller caliber can limit infusion rate compared with central lines. Documentation should specify the substance transfused and confirm venous rather than arterial delivery, since peripheral veins are more prone to infiltration or phlebitis with viscous products, which can affect infusion tolerance and the need for site rotation during multi-unit transfusions.
Approach: Percutaneous
In Administration, Percutaneous denotes a substance delivered by needle injection through the skin, such as an intramuscular or subcutaneous injection, without cutting or scope guidance. It differs from External, where the substance is applied to the skin surface itself, and from Via Natural or Artificial Opening, where it is introduced through an orifice rather than through a puncture.
Substance: Hematopoietic Stem/Progenitor Cells, Genetically Modified
This value specifies administration of hematopoietic stem or progenitor cells that have been genetically modified, used in advanced cellular therapies such as gene-modified transplants for certain inherited or malignant blood disorders. It differs from unmodified Bone Marrow or Whole Blood products by the genetic engineering step performed on the cells before infusion, and from embryonic stem cells by its blood-forming tissue origin.
Qualifier: Autologous
This Administration qualifier indicates that the substance given, typically blood or blood products, came from the patient's own body, as in autologous blood transfusion using previously collected self-donated units. It distinguishes the source of the product from nonautologous transfusions, which use blood or tissue collected from another individual.
Coding & Documentation
Assigning a code from this family depends on documentation specifying the exact blood product given, whether it was autologous or from a donor, and the vessel or route used for infusion, such as a peripheral vein or central venous catheter. Nursing and physician notes recording units transfused, product type, and any reaction are the primary support for the code. A recurring error is selecting the wrong substance qualifier, for example coding platelets when frozen plasma was actually given, or overlooking that autologous blood requires a different qualifier than banked donor blood. Coders should also confirm the route matches what is documented rather than defaulting to peripheral vein.